# 10x Genomics

**Source:** https://geo.sig.ai/brands/10x-genomics  
**Vertical:** Life Sciences & BioTech  
**Subcategory:** Genomics & Single-Cell Analysis  
**Tier:** Established  
**Website:** 10xgenomics.com  
**Last Updated:** 2026-04-22

## Summary

Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms power cell-type discovery in oncology, neuroscience, and immunology.

## Company Overview

10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabling researchers to analyze gene expression across thousands of individual cells simultaneously—a capability that transformed cell biology, immunology, and cancer research. The Visium Spatial Gene Expression platform extended this to map gene expression within intact tissue architecture.\n\n10x Genomics' instruments and consumables are used by leading academic research centers, pharmaceutical companies, and translational medicine teams to profile the cellular composition of tumors, map the nervous system, characterize immune responses, and develop cell therapies. The company reported full-year 2025 revenue of $642.8 million, up from $610.8 million in 2024, and guides to $600–$625 million for 2026 amid cautious biotech funding conditions.\n\nThe company is transitioning toward a broader multi-omics portfolio including ATAC-seq, protein detection, and spatial multi-omics, while defending market position against competition from Parse Biosciences, Vizgen, and others. Despite near-term funding headwinds in academic markets, 10x Genomics remains a foundational infrastructure provider for the cell atlas era of biology.

## Frequently Asked Questions

### What is 10x Genomics' flagship product?
The Chromium platform for single-cell RNA sequencing (scRNA-seq) is 10x Genomics' flagship, enabling gene expression profiling of thousands of individual cells simultaneously.

### What was 10x Genomics' FY2025 revenue?
10x Genomics reported $642.8 million in FY2025 revenue, up from $610.8 million in 2024, with 2026 guidance of $600–$625 million.

### What is the Visium platform used for?
Visium is 10x Genomics' spatial transcriptomics platform, mapping where genes are expressed within intact tissue sections, enabling spatial understanding of tumor microenvironments and tissue architecture.

### What products does 10x Genomics sell and what are their prices?
10x Genomics sells two primary platforms: the Chromium system for single-cell sequencing (instruments typically priced in the $75,000–$100,000 range) and the Visium Spatial Gene Expression platform for spatial transcriptomics. Reagent kits and library preparation consumables are sold on a recurring basis, typically ranging from a few hundred to several thousand dollars per run depending on the assay. Pricing varies by geography and volume commitments.

### Who are 10x Genomics' primary customers?
10x Genomics serves academic research institutions, hospital-based translational research labs, pharmaceutical and biotech companies conducting drug discovery and development, and government-funded research centers. Top customers include leading cancer centers, major pharmaceutical companies studying immunology and oncology, and university core genomics facilities worldwide.

### How does 10x Genomics differentiate from competitors like Parse Biosciences and BD Biosciences?
10x Genomics differentiates on throughput, resolution, and breadth of assay types. Its Chromium platform supports simultaneous measurement of gene expression, protein levels (via CITE-seq), chromatin accessibility (ATAC-seq), and V(D)J immune profiling from the same cells. Visium HD offers subcellular spatial resolution. Competitors like Parse Biosciences offer lower-cost, instrument-free fixed single-cell workflows, but 10x maintains superior data quality benchmarks and the broadest assay menu.

### What recent milestones has 10x Genomics achieved?
10x Genomics launched Visium HD in 2024, achieving subcellular spatial resolution without requiring specialized imaging infrastructure. The company also introduced Xenium In Situ for ultra-high-plex spatial RNA imaging in tissue sections, expanding into the spatial biology market alongside its sequencing-based portfolio. As of 2025, the company has sold instruments into thousands of labs globally and published data from over 10,000 research publications citing its platforms.

### What integrations and ecosystem does 10x Genomics support?
10x Genomics integrates with major next-generation sequencing platforms including Illumina and Element Biosciences. Its analysis software, Space Ranger and Cell Ranger, outputs data compatible with R (Seurat, Bioconductor) and Python (Scanpy, AnnData) bioinformatics ecosystems. The company also partners with computational biology software vendors like Benchling and has an active community ecosystem through 10x Community forums and published pipelines on GitHub.

## Tags

b2b, global, public, enterprise, healthtech, hardware, analytics, platform

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-22.*